Rough Road Ahead for Stocks? And an Under-the-Radar Winner in the Weight Loss Boom 9/25/23
The yield on 10-year treasurys crossed the 4.5% mark for the first time since October 2007, but it's the benchmark’s relationship with the 2 year that caught the attention of one of our traders. Why the steeply steepening yield curve could be setting up equities for a problem period. Plus manufacturing giant Jacobs Solutions counts Eli Lilly and Novo Nordisk as two of its biggest customers. How the company is benefiting from the surging demand for weight-loss drugs.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More description
The yield on 10-year treasurys crossed the 4.5% mark for the first time since October 2007, but it's the benchmark’s relationship with the 2 year that caught the attention of one of our traders. Why the steeply steepening yield curve could be setting up equities for a problem period. Plus manufacturing giant Jacobs Solutions counts Eli Lilly and Novo Nordisk as two of its biggest customers. How the company is benefiting from the surging demand for weight-loss drugs.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.